HOME
The Info List - Johnson And Johnson



--- Advertisement ---


(i) (i) (i) (i) (i)

JOHNSON & JOHNSON is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500 .

Johnson & Johnson
Johnson & Johnson
is headquartered in New Brunswick, New Jersey
New Brunswick, New Jersey
, the consumer division being located in Skillman, New Jersey . The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $70.1 billion during calendar year 2015.

Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid
Band-Aid
Brand line of bandages, Tylenol medications, Johnson\'s baby products, Neutrogena skin and beauty products , Clean & Clear facial wash and Acuvue contact lenses .

CONTENTS

* 1 History

* 1.1 Foundation and early history * 1.2 1959: McNeil Consumer Healthcare * 1.3 1959: Cilag * 1.4 1961: Janssen Pharmaceuticals * 1.5 1998: DePuy
DePuy
* 1.6 1999: Janssen Biotech, Inc.

* 1.7 Ethicon, Inc

* 1.7.1 Ethicon Endo-Surgery, Inc.

* 1.8 Actelion
Actelion
* 1.9 Johnson & Johnson
Johnson & Johnson
Vision Care, Inc * 1.10 2010 onwards * 1.11 Structure

* 2 Corporate governance

* 3 JNJ Headquarters and the New Brunswick gentrification

* 3.1 Chairmen

* 4 Products

* 4.1 Pharmaceuticals * 4.2 Medical devices * 4.3 Consumer health

* 5 Environmental record

* 6 Recalls and litigation

* 6.1 1982 Chicago Tylenol murders * 6.2 2010 children\'s product recall * 6.3 2010 hip-replacement recall * 6.4 2010 Tylenol recall * 6.5 Shareholders lawsuit * 6.6 Illegal marketing of Risperdal * 6.7 Foreign bribery * 6.8 Consumer Fraud Settlements * 6.9 Use of the Red Cross symbol * 6.10 Boston Scientific lawsuits * 6.11 Patent-infringement case against Abbott * 6.12 Vaginal mesh implants * 6.13 Baby powder

* 7 See also * 8 References * 9 External links

HISTORY

Johnson & Johnson
Johnson & Johnson
operates over 250 companies in what is termed "the Johnson Consumer Healthcare, Medical Devices and Pharmaceuticals.

JOHNSON & JOHNSON FAMILY OF COMPANIES

CONSUMER HEALTHCARE MEDICAL DEVICES PHARMACEUTICALS

Baby Care Skin & Hair Care Wound Care and Topicals Oral Health Care Women’s Health McNeil Consumer Healthcare Over-The-Counter Medicines Nutritionals Advanced Sterilization Products Animas Corporation Biosense Webster DePuy
DePuy
Synthes Ethicon, Inc. Janssen Diagnostics BVBA Johnson & Johnson
Johnson & Johnson
Vision Care, Inc. LifeScan, Inc. Mentor Janssen Janssen R"> Robert Wood Johnson

Inspired by a speech by antiseptic advocate Joseph Lister , Robert Wood Johnson joined his brothers James Wood Johnson and Edward Mead Johnson to create a line of ready-to-use surgical dressings in 1885. The company produced its first products in 1886 and incorporated in 1887.

Robert Wood Johnson served as the first president of the company. He worked to improve sanitation practices in the nineteenth century, and lent his name to the Robert Wood Johnson University Hospital in New Brunswick, New Jersey. Upon his death in 1910, he was succeeded in the presidency by his brother James Wood Johnson until 1932, and then by his son, Robert Wood Johnson II .

Robert Wood Johnson's granddaughter, Mary Lea Johnson Richards , was the first baby to appear on a Johnson ">

1959: MCNEIL CONSUMER HEALTHCARE

McNeil Consumer Healthcare was founded on March 16, 1879 by 23-year-old Robert McNeil. In 1904, one of McNeil's sons, Robert Lincoln McNeil, became part of the company and together they created McNeil Laboratories in 1933. The company focused on direct marketing of prescription drugs to hospitals, pharmacists, and doctors. Development of acetaminophen began under the leadership of Robert L. McNeil, Jr. , who later served as the firm's chairman. In 1959, Johnson McNeil medicals products and McNeil Consumer Products Company (also known as McNeil Consumer Healthcare). The focus of McNeil medicals products is to market prescription drugs. In 1993 McNeil medicals products merged with the Ortho Pharmaceutical to form Ortho-McNeil Pharmaceutical
Ortho-McNeil Pharmaceutical
. In 2001 McNeil Consumer Healthcare changed its name to McNeil Consumer & Specialty medicals products. However, it was later changed to "McNeil Consumer Healthcare". The company markets over-the-counter and prescription medicals products including complete lines of Tylenol and Motrin IB (ibuprofen ) products for adults and children.

1959: CILAG

In 1933, Swiss chemist Bernhard Joos set up a small research laboratory in Schaffhausen
Schaffhausen
, Switzerland. This set the basis for the founding of Chemische Industrie-Labor AG (Chemical Industry Laboratory AG or Cilag) on 12 May 1936. In 1959, Cilag joined the Johnson & Johnson family of companies. In the early nineties, the marketing organizations of Cilag and Janssen Pharmaceutica were joined to form Janssen-Cilag . The non-marketing activities of both companies still operate under their original name. Cilag continues to have operations under the Cilag name in Switzerland, ranging from research and development through manufacturing and international services. In August 2014, Cilag acquired Covagen a biopharmaceutical company which specialises in the development of multi-specific protein based therapeutics. As part of the acquisition Cilag wll gain access to Covagen’s lead drug candidate, COVA 322 , a bi-specific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is in a Phase Ib study for psoriasis .

1961: JANSSEN PHARMACEUTICALS

Janssen Pharmaceuticals can be traced back to 1933. In 1933, Constant Janssen , the father of Paul Janssen, acquired the right to distribute the pharmaceutical products of Richter , a Hungarian pharmaceutical company, for Belgium, the Netherlands and Belgian Congo
Belgian Congo
. On 23 October 1934, he founded the N.V. Produkten Richter in Turnhout . After the Second World War, the name for the company products was changed to Eupharma, although the company name Richter would remain until 1956.

Paul Janssen founded his own research laboratory in 1953 on the third floor of the building in the Statiestraat, still within the Richter-Eurpharma company of his father. On 5 April 1956, the name of the company was changed to NV Laboratoria Pharmaceutica C. Janssen (named after Constant Janssen). On 2 May 1958, the research department in Beerse became a separate legal entity, the N.V. Research Laboratorium C. Janssen. On 24 October 1961, the company was acquired by the American corporation Johnson & Johnson. On 10 February 1964, the name was changed to Janssen Pharmaceutica N.V. Between 1990 and 2004, Janssen Pharmaceuticals expanded worldwide, with the company growing in size to approximately 28000 employees worldwide. In 1999, clinical research and non-clinical development become a global organization within Johnson & Johnson. In 2001, part of the research activities was transferred to the United States
United States
with the reorganization of research activities in the Johnson & Johnson Pharmaceutical Research and Development organization. The research activities of the Janssen Research Foundation and the R.W. Johnson Pharmaceutical Research Institute were merged into the new global research organization. On 27 October 2004, the Paul Janssen Research Center, for discovery research, was inaugurated.

In August 2013, the company acquired Aragon Pharmaceuticals, Inc. . In November 2014, the company acquired Alios BioPharma, Inc. for $1.75 billion. As a result of the purchase, Alios was incorporated into the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson. In March 2015, Janssen licensed Tipofarnib (a farnesyl transferase inhibitor) to Kura Oncology who will assume sole responsibility for developing and commercialising the anti-cancer drug. Later in the same month the company announced that Galapagos Pharma and regained the rights to the anti-inflammatory drug candidate GLPG1690 as well as two other compounds including GLPG1205 (a first-in-class inhibitor of GPR84 ). Finally, in March, the company acquired XO1 Limited In November 2015, the company acquired Novira Therapeutics, Inc. , gaining the lead candidate, NVR 3-778 .

1998: DEPUY

DePuy
DePuy
was acquired by J&J in 1998, rolling it into the Johnson & Johnson Medical Devices group. On June 14, 2012, Johnson and Johnson completed the acquisition of Synthes for $19.7 billion, which was then integrated with the DePuy
DePuy
franchise to establish the DePuy Synthes Companies of Johnson Codman DePuy
DePuy
Ireland Unlimited Company announced it would acquire Neuravi, a company with a portfolio of products for hemorrhagic and ischemic strokes for an undisclosed sum, with Codman Neuro being behind the deal. In June, DePuy
DePuy
Synthes Products, Inc. announced it would acquire Innovative Surgical Solutions, LLC (trading as Sentio, LLC) for an undisclosed sum, bolstering the company's technology for innovative nerve localisation in spinal surgery.

1999: JANSSEN BIOTECH, INC.

Janssen Biotech, Inc., formerly known as Centocor
Centocor
Biotech, Inc., is a biotechnology company that was founded in Philadelphia
Philadelphia
in 1979. In 1982, Centocor
Centocor
transitioned into a publicly traded company. In 1999, Centocor
Centocor
became a wholly owned subsidiary of Johnson & Johnson. Since the acquisition, Janssen Biotech
Janssen Biotech
increased its annual sales from $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million. In 2008, Centocor, Inc. and Ortho Biotech Inc. merged to form Centocor
Centocor
Ortho Biotech Inc. In June 2010, Centocor
Centocor
Ortho Biotech acquired RespiVert , a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. In June 2011, Centocor
Centocor
Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity. In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate (MGD011 ) which targets both CD19 and CD3 proteins in treating B-cell
B-cell
malignant tumours. This could net MacroGenics up to $700 million. In January 2015, the company announced it will utilise Isis Pharmaceuticals ' RNA-targeting technology to discover and develop antisense drugs targeting autoimmune disorders of the gastrointestinal tract , with the partnership potentially generating up to $835 million for Isis.

ETHICON, INC

In 1915, George F. Merson opened a facility in Edinburgh for the manufacturing, packaging and sterilizing of catgut, silk and nylon sutures. Johnson & Johnson
Johnson & Johnson
acquired Mr. Merson’s company in 1947, and this was renamed Ethicon Suture Laboratories. In 1953 this became Ethicon Inc. In 1992, Ethicon was restructured, and Ethicon Endo-Surgery, Inc. became a separate corporation. During the 1990s, Ethicon diversified into new and advanced products and technologies and formed four different companies under the Ethicon umbrella, each of which specialize in different products. In 2008 J&J announced it would acquire Mentor Corporation for $1 billion and merge its operations into Ethicon. In March 2016, J&Js Ethicon business unit announced it would acquire NeuWave Medical, Inc . In January 2017, J&J subsidiary Ethicon announced it would acquire Megadyne Medical Products, Inc., a medical device company that develops, manufactures and markets electrosurgical tools. In February 2017, Ethicon acquired medical device manufacturer, Torax Medical for an undisclosed sum.

Ethicon Endo-Surgery, Inc.

Ethicon Endo-Surgery was part of Ethicon Inc. until 1992, when it became a separate corporate entity under the J&J umbrella.

ACTELION

In January 2017, J&J fought off competition from Sanofi
Sanofi
to acquire Swiss drugmaker Actelion
Actelion
. Later in the month J&J announced a $30 billion deal to purchase the Swiss company Actelion
Actelion
and to spin off its research and development unit, into a separate legal entity. In March, the company declared its tender offer for Swiss biotechnology company Actelion
Actelion
successful on Friday, reporting that Janssen Holding GmbH controlled 77.2 percent of the voting rights after the main offer period, equating to 83,195,346 Actelion
Actelion
shares. In keeping with earlier agreements, the company announced its intention to delist Actelion, whilst spinning out its drug discovery operations and early-stage clinical development assets into a newly created Swiss-based biopharmaceutical company, Idorsia Ltd . J&J will control 16% of Idorsia, with the ability to raise their stake to 32% through convertible notes.

JOHNSON & JOHNSON VISION CARE, INC

In July 2016, J&J announced its intention to acquire the privately held company, Vogue International LLC, boosting Johnson & Johnson Consumer Inc. In September of the same year, J&J announced it would acquire Abbott Medical Optics from Abbott Laboratories for $4.325 billion, adding the new division into Johnson & Johnson
Johnson & Johnson
Vision Care, Inc.

In July 2017, Johnson & Johnson
Johnson & Johnson
Vision Care, Inc announced that its Abbott Medical Optics subsidiary would acquire TearScience , who recently received FDA approval for an office-based approach to imaging meibomian glands and treating meibomian gland dysfunction . In September, the company acquired subscription-based contact lens startup Sightbox.

2010 ONWARDS

In October 2010, J"> J"> Johnson & Johnson
Johnson & Johnson
office in Ontario

STRUCTURE

The following is an illustration of the company's structure, maintained though a number of mergers ">JOHNSON padding:0;">

Johnson padding:0;">

Baby Care

Skin border-left:1px solid;vertical-align:top;text-align:center;">

Wound Care and Topicals

Oral Health Care

Women’s Health

Over-The-Counter Medicines

Nutritionals

Vogue International LLC

Medical Devices Division

Advanced Sterilization Products

Animas Corporation

Biosense Webster

Coherex Medical, Inc.

DePuy
DePuy
Synthes

Codman padding:0;">

Pulsar Vascular Inc.

Neuravi

DePuy
DePuy
Mitek, Inc.

DePuy
DePuy
Orthopaedics, Inc.

Biomedical Enterprises, Inc.

DePuy
DePuy
Spine, Inc

DePuy
DePuy
Synthes Products, Inc

Sentio, LLC

Olive Medical Corporation

Ethicon, Inc.

Mentor

Acclarent

NeuWave Medical, Inc

Megadyne Medical Products, Inc.

Torax Medical

Janssen Diagnostics BVBA

Johnson padding:0;">

Vistakon

Abbott Medical Optics

TearScience

Sightbox

LifeScan, Inc.

Ethicon Endo-Surgery

Pharmaceuticals Division

Janssen Pharmaceutica

Cilag

Covagen

Janssen-Cilag

Aragon Pharmaceuticals, Inc.

Alios BioPharma, Inc.

Novira Therapeutics, Inc.

Actelion
Actelion

Janssen Rborder-left:1px solid;vertical-align:top;text-align:center;">

Janssen Healthcare Innovation

Janssen Biotech, Inc.

Ortho Biotech Inc.

RespiVert

Janssen Therapeutics

Janssen Diagnostics

Janssen Scientific Affairs

Crucell

Janssen-Ortho

McNeil Nutritional LLC

Mead Johnson (Sold to Reckitt Benckiser)

CORPORATE GOVERNANCE

Current members of the board of directors of Johnson & Johnson
Johnson & Johnson
are: Mary Sue Coleman , James G. Cullen, Dominic Caruso, Michael M.E. Johns, Ann Dibble Jordan , Arnold G. Langbo, Susan L. Lindquist , Leo F. Mullin, William Perez , Steven S. Reinemund, David Satcher
David Satcher
, and William C. Weldon .

Sandi Peterson has served as Group Worldwide Chairman since 2012.

On top of Alex Gorsky and Sandi Peterson, current members of Executive Committees of Johnson & Johnson
Johnson & Johnson
are: Dominic Caruso, Peter Fasolo, Paul Stoffels, and Michael Sneed.

JNJ HEADQUARTERS AND THE NEW BRUNSWICK GENTRIFICATION

The company has historically been located on the Delaware and Raritan Canal in New Brunswick. The company considered moving its headquarters out of New Brunswick in the 1960s, but decided to stay in the town after city officials promised to gentrify downtown New Brunswick by demolishing old buildings and constructing new ones.

While New Brunswick lost at least one historic edifice (the inn where Rutgers University began) to the redevelopment, the gentrification did attract people back to New Brunswick. Johnson & Johnson
Johnson & Johnson
hired Henry N. Cobb from Pei Cobb Freed Intelence ( Etravirine ), a non-nucleoside HIV polymerase inhibitor; and Prezista (darunavir ), an HIV protease inhibitor. Telaprevir
Telaprevir
sales are expected to decline due to the recent approval of treatment regimens that are more efficacious and much better tolerated. Etravirine and darunavir are notable for their high barriers to resistance development. Darunavir
Darunavir
in combination with HIV polymerase inhibitors is recommended as a first line treatment option for treatment naive persons with HIV infection but etravirine is approved only for use in treatment-experienced patients, owing in part to its requirement for twice-daily dosing.

The company's CNS products include the ADHD drug Concerta (methylphenidate extended release), and the long-acting injectable antipsychotics Invega Sustenna (paliperidone palmitate ) and Risperdal Consta (risperidone ). Invega Sustenna and Risperdal Consta were the first widely utilized long-acting depot injections for the treatment of schizophrenia. Designed to address the issue of poor patient compliance with oral therapy, they are administered by intramuscular injection at intervals of 2 weeks and one month, respectively. Only minimal improvements in outcomes relative to the oral versions of these drugs were observed in the clinical trial setting, but some evidence suggests that the advantages of long-acting injections in clinical practice may be greater than is readily demonstrated in the environment of a clinical trial.

Oncology products include Velcade (bortezomib ), for the treatment of multiple myeloma and mantle cell lymphoma and Zytiga (abiraterone ), an androgen antagonist for the treatment of prostate cancer. In clinical trials, abiraterone treatment was associated with a 4.6 to 5.2 survival advantage when used either before or after chemotherapy with platinum based drugs. On December 31, 2012, the Food and Drug Administration approved Sirturo (bedaquiline), a Johnson -webkit-column-count: 2; column-count: 2;">

* Aesthetics (Ethicon, Mentor) * Arrhythmias (Biosense Webster) * Bariatric Surgery for Obesity (Ethicon) * Cardiovascular Disease (Biosense Webster, Inc.) * Diabetes Care (LifeScan, Animas Corporation) * Ear, Nose, and Throat Conditions (Acclarent) * General Surgery (Ethicon, Codman Neuro) * Hernia Surgery (Ethicon) * Insulin Delivery Devices (Animas) * Neurovascular Disease (Codman Neuro, DePuy
DePuy
Synthes) * Orthopaedics ( DePuy
DePuy
Synthes): Joint Reconstruction, Trauma, Spine, Sports Medicine and Power Tools * Self-Measured Blood Glucose Monitors (LifeScan) * Surgical Instruments and Infection Prevention(Advanced Sterilization Products) * Urologic Surgery (Ethicon) * Vision Care (VISTAKON®)

CONSUMER HEALTH

Sectors in which the company is active include:

* Baby Care * Nutritionals * Oral Health Care * Over-the-Counter Medicines * Skin & Hair Care * Vision Care * Wound Care & Topicals

ENVIRONMENTAL RECORD

Johnson & Johnson
Johnson & Johnson
has set several positive goals to keep the company environmentally friendly and was ranked third among the United States's largest companies in Newsweek 's "Green Rankings". Some examples are the reduction in water use, waste, and energy use and an increased level of transparency. Johnson & Johnson
Johnson & Johnson
agreed to change its packaging of plastic bottles used in the manufacturing process, switching their packaging of liquids to non-polycarbonate containers. The corporation is working with the Climate Northwest Initiative and the EPA National Environmental Performance Track program. As a member of the national Green Power Partnership, Johnson & Johnson
Johnson & Johnson
operates the largest solar power generator in Pennsylvania at its site in Spring House, PA .

RECALLS AND LITIGATION

1982 CHICAGO TYLENOL MURDERS

Main article: Chicago Tylenol murders

On September 29, 1982, a "Tylenol scare" began when the first of seven individuals died in Chicago metropolitan area , after ingesting Extra Strength Tylenol that had been deliberately laced with cyanide . Within a week, the company pulled 31 million bottles of capsules back from retailers, making it one of the first major recalls in American history. The incident led to reforms in the packaging of over-the-counter substances and to federal anti-tampering laws. The case remains unsolved and no suspects have been charged. Johnson & Johnson's quick response, including a nationwide recall, was widely praised by public relations experts and the media and was the gold standard for corporate crisis management.

2010 CHILDREN\'S PRODUCT RECALL

Main article: 2010 Johnson & Johnson
Johnson & Johnson
children\'s product recall

On April 30, 2010, McNeil Consumer Healthcare , a subsidiary of Johnson and Johnson, voluntarily recalled 43 over-the-counter children's medicines, including Tylenol , Tylenol Plus, Motrin , Zyrtec
Zyrtec
and Benadryl . The recall was conducted after a routine inspection at a manufacturing facility in Fort Washington, Pennsylvania , United States
United States
revealed that some "products may not fully meet the required manufacturing specifications". Affected products may contain a "higher concentration of active ingredients" or exhibit other manufacturing defects. Products shipped to Canada, Dominican Republic, Guam
Guam
, Guatemala, Jamaica, Puerto Rico
Puerto Rico
, Panama, Trinidad and Tobago, the United Arab Emirates, Kuwait and Fiji were included in the recall. In a statement, Johnson & Johnson
Johnson & Johnson
said "a comprehensive quality assessment across its manufacturing operations" was underway. A dedicated website was established by the company listing affected products and other consumer information.

2010 HIP-REPLACEMENT RECALL

Main article: 2010 DePuy
DePuy
Hip Recall

On August 2009, 2010, DePuy, a subsidiary of American giant Johnson & Johnson, recalled its ASR (articular surface replacement) hip prostheses from the market. DePuy
DePuy
said the recall was due to unpublished National Joint Registry data showing a 12% revision rate for resurfacing at five years and an ASR XL revision rate of 13%. All hip prostheses fail in some patients, but it is expected that the rate will be about 1% a year. Pathologically, the failing prosthesis had several effects. Metal debris from wear of the implant led to a reaction that destroyed the soft tissues surrounding the joint, leaving some patients with long term disability. Ions of cobalt and chromium—the metals from which the implant was made—were also released into the blood and cerebral spinal fluid in some patients.

In March 2013, a jury in Los Angeles ordered Johnson & Johnson
Johnson & Johnson
to pay more than $8.3 million in damages to a Montana man in the first of more than 10,000 lawsuits pending against the company in connection with the now-recalled DePuy
DePuy
hip.

Some lawyers and industry analysts have estimated that the suits ultimately will cost Johnson & Johnson
Johnson & Johnson
billions of dollars to resolve.

2010 TYLENOL RECALL

In 2010 and 2011, Johnson & Johnson
Johnson & Johnson
voluntarily recalled some over-the-counter products including Tylenol due to an odor caused by tribromoanisole. In this case, 2,4,6-tribromophenol was used to treat wooden pallets on which product packaging materials were transported and stored.

SHAREHOLDERS LAWSUIT

In 2010 a group of shareholders sued the board for allegedly failing to take action to prevent serious failings and illegalities since the 1990s, including manufacturing problems, bribing officials, covering up adverse effects and misleading marketing for unapproved uses. The judge initially dismissed the case in September 2011, but allowed the plaintiffs opportunity to refile at a later time. In 2012 Johnson and Johnson proposed a settlement with the shareholders, whereby the company would institute new oversight, quality and compliance procedures binding for five years.

ILLEGAL MARKETING OF RISPERDAL

Juries in several US states have found J&J guilty of concealing the adverse effects of Janssen Pharmaceuticals ' antipsychotic medication Risperdal , produced by its unit, in order to promote it to doctors and patients as better than cheaper generics, and of falsely marketing it for treating patients with dementia . States that have awarded damages include Texas
Texas
($158 million), South Carolina ($327 million), Louisiana
Louisiana
($258 million), and most notably Arkansas
Arkansas
($1.2 billion).

In 2010, the United States
United States
Department of Justice joined a whistleblowers suit accusing the company of illegally marketing Risperdal through Omnicare
Omnicare
, the largest company supplying pharmaceuticals to nursing homes. The allegations include that J&J were warned by the U.S. Food and Drug Administration (FDA) not to promote Risperdal as effective and safe for elderly patients, but they did so, and that they paid Omnicare
Omnicare
to promote the drug to care home physicians. The settlement was finalized on November 4, 2013, with J&J agreeing to pay a penalty of around $2.2 billion, "including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion."

Johnson & Johnson
Johnson & Johnson
has also been subject to congressional investigations related to payments given to psychiatrists to promote its products and ghost write articles, notably Joseph Biederman and his pediatric bipolar disorder research unit.

FOREIGN BRIBERY

In 2011, J&J settled litigation brought by the US Securities and Exchange Commission under the Foreign Corrupt Practices Act and paid around $70M in disgorgement and fines. J&J's employees had given kickbacks and bribes to doctors in Greece
Greece
, Poland
Poland
, and Romania
Romania
to obtain business selling drugs and medical devices and had bribed officials in Iraq
Iraq
to win contracts under the Oil for Food program. J&J fully cooperated with the investigation once the problems came to light.

CONSUMER FRAUD SETTLEMENTS

In May 2017, J"> Flag of the Red Cross Further information: Emblems of the International Red Cross and Red Crescent Movement § Use of the emblems

Johnson & Johnson
Johnson & Johnson
registered the Red Cross as a U.S. trademark for "medicinal and surgical plasters" in 1905 and has used the design since 1887. The Geneva Conventions
Geneva Conventions
, which reserved the Red Cross emblem for specific uses, were first approved in 1864 and ratified by the United States
United States
in 1882. However, the emblem was not protected by U.S. law for the use of the American Red Cross and the U.S. military until after Johnson & Johnson
Johnson & Johnson
had obtained its trademark. A clause in this law (now 18 U.S.C. 706) permits this pre-existing uses of the Red Cross to continue.

A declaration made by the U.S. upon its ratification of the 1949 Geneva Conventions
Geneva Conventions
includes a reservation that pre-1905 U.S. domestic uses of the Red Cross, such as Johnson & Johnson's, would remain lawful as long as the cross is not used on "aircraft, vessels, vehicles, buildings or other structures, or upon the ground," i.e., uses which could be confused with its military uses. This means that the U.S. did not agree to any interpretation of the 1949 Geneva Conventions that would overrule Johnson & Johnson's trademark. The American Red Cross continues to recognize the validity of Johnson & Johnson's trademark.

In August 2007, Johnson & Johnson
Johnson & Johnson
filed a lawsuit against the American Red Cross (ARC), demanding that the charity halt the use of the red cross symbol on products it sells to the public, though the company takes no issue with the charity's use of the mark for non-profit purposes. In May 2008, the judge in the case dismissed most of Johnson & Johnson's claims, and a month later the two organizations announced a settlement had been reached in which both parties would continue to use the symbol.

BOSTON SCIENTIFIC LAWSUITS

Since 2003, Johnson & Johnson
Johnson & Johnson
and Boston Scientific have both claimed that the other had infringed on their patents covering heart stent medical devices. The litigation was settled when Boston Scientific agreed to pay $716 million to Johnson & Johnson
Johnson & Johnson
in September 2009 and an additional $1.73 billion in February 2010. Their dispute was renewed in 2014, now on the grounds of a contract dispute.

PATENT-INFRINGEMENT CASE AGAINST ABBOTT

In 2007, Johnson & Johnson
Johnson & Johnson
sued Abbott Laboratories over the development and sale of the arthritis drug Humira
Humira
. Johnson & Johnson claimed that Abbott used technology patented by New York University and licensed exclusively to Johnson & Johnson's Centocor
Centocor
division to develop Humira. Johnson & Johnson
Johnson & Johnson
won the court case, and in 2009 Abbott was ordered to pay Johnson & Johnson
Johnson & Johnson
$1.17 billion in lost revenues and $504 million in royalties. The judge also added $175.6 million in interest to bring the total to $1.84 billion. This was the largest patent-infringement award in U.S. history until the 2013 decision against Teva in favor of Takeda
Takeda
and Pfizer
Pfizer
for over 2.1 billion dollars. Abbott has since successfully reversed the verdict at appeal.

VAGINAL MESH IMPLANTS

Tens of thousands of women worldwide have taken legal action against Johnson & Johnson
Johnson & Johnson
after suffering serious complications following a vaginal mesh implant procedure. In 2016 the U.S. states of California and Washington filed a lawsuit against the company, accusing it of deception. More than 700 women began a class action against the company in the Federal Court of Australia
Federal Court of Australia
in 2017, telling the court they "suffered irreparable, debilitating pain after the devices began to erode into surrounding tissue and organs, causing infections and complications." The class action alleged that Johnson & Johnson, which "aggressively marketed" the implants "failed to properly warn patients and surgeons of the risk, or test the devices adequately."

BABY POWDER

In February 2016, J&J was ordered to pay $72 million in damages to the family of Jacqueline Fox, a 62-year-old woman who died of ovarian cancer in 2015. She had been sprinkling Johnson's Baby Powder
Baby Powder
on her underwear nearly every day since she was a teenager. J&J claimed that the safety of cosmetic talc is supported by decades of scientific evidence and it plans to appeal the verdict. The British charity, Ovacome was quoted as saying that while there were 16 studies which showed that using talc increased the risk of ovarian cancer by around a third and that a 2013 review of US studies came up with similar results for genital, but not general talcum powder use, J&J were not convinced that the results were reliable. Furthermore, Ovacome said, " Ovarian cancer is a rare disease, and increasing a small risk by a third still gives a small risk."

By March 2017, over 1,000 U.S. women had sued J the company says that 70 percent of its Baby Powder
Baby Powder
is used by adults.

On August 21, 2017, a California
California
jury ordered Johnson & Johnson
Johnson & Johnson
to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene. The verdict included $70 million in compensatory damages and $347 million in punitive damages. J of whom only two were from Missouri. Subsequently, it also would kill three other recent St. Louis jury verdicts of more than $ 200 million combined.

SEE ALSO

* New Jersey portal * Companies portal * Medicine portal

* Frederick Barnett Kilmer – Director of Scientific Laboratories from 1889 to 1934. * Zodiac – Historic schooner built for the Johnson family heirs.

REFERENCES

* ^ A B C D E F "Johnson ">(XBRL). United States
United States
Securities and Exchange Commission. February 5, 2016. * ^ anonymous. "VisionCare Corporate - Our History". jnjvc.com. * ^

Wikimedia Commons has media related to JOHNSON & JOHNSON .

* Official website

*

* Business data for Johnson ;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">v

* t * e

Johnson border-left-width:2px;border-left-style:solid;width:100%;padding:0px"> CURRENT: Alex Gorsky , Chairman and CEO

* Robert Wood Johnson I * James Wood Johnson * Robert Wood Johnson II * Robert Wood Johnson III * Philip B. Hofmann * Richard B. Sellars * James E. Burke * Ralph S. Larsen

SELECTED SUBSIDIARIES

* ALZA
ALZA
Corporation * Cilag * Crucell * DePuy, Inc. * Ethicon Endo-Surgery, Inc. * Ethicon, Inc. * Independence Technology , LLC * J&J PRD * Janssen Biotech
Janssen Biotech
* Janssen Pharmaceutica * LifeScan * McNeil Consumer border-left-width:2px;border-left-style:solid;width:100%;padding:0px">

* Acuvue * Aveeno * Band-Aid
Band-Aid
* Benadryl * Benecol
Benecol
(US license) * Bengay * Caladryl * Clean ;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">v

* t * e

Pharmaceutical companies of the United States
United States

CURRENT

* Abbott Laboratories * Acorda Therapeutics * Aderis Pharmaceuticals * Advaxis
Advaxis
* Alcon * Alexion Pharmaceuticals * Alkermes * Allergan * Amgen
Amgen
* Avax Technologies * Baxter International * BioCryst Pharmaceuticals * Biogen
Biogen
* Bioverativ * Biovest * Biovista * Bristol-Myers Squibb * Century Pharmaceuticals * Ceragenix Pharmaceuticals * Combe Incorporated * CytoSport
CytoSport
* CytRx * Danco Laboratories * Eli Lilly and Company

* Endo Pharmaceuticals

* Par Pharmaceutical

* Galena Biopharma * Genentech
Genentech
* Gilead Sciences
Gilead Sciences
* Institute for OneWorld Health * Intercept Pharmaceuticals

* Johnson & Johnson
Johnson & Johnson

* Ethicon * Janssen Biotech
Janssen Biotech
* McNeil Consumer Healthcare * Ortho-McNeil Pharmaceutical
Ortho-McNeil Pharmaceutical

* Kinetic Concepts * Mallinckrodt * McKesson Corporation * Melinta Therapeutics (formerly Rib-X Pharmaceuticals) * Melior Discovery
Melior Discovery
* Mentholatum
Mentholatum
* Merck & Co.
Merck & Co.
* Myriad Genetics * Northwest Biotherapeutics * Norwich Pharma Services
Norwich Pharma Services
* NovaBay Pharmaceuticals * Ovation Pharmaceuticals * Perrigo

* Pfizer
Pfizer

* Hospira * Searle

* Pharmaceutical Product Development * Prasco Laboratories * Procter border-left-width:2px;border-left-style:solid;width:100%;padding:0px">

* Alza
Alza
* Amylin Pharmaceuticals * ARIAD Pharmaceuticals * Biolex * Bradley Pharmaceuticals * CancerVax * Cephalon * CoTherix * Covance * Covidien
Covidien
* Cubist Pharmaceuticals * Cutter Laboratories * DNAPrint Genomics * Epix Pharmaceuticals * Forest Laboratories * Genta * ImClone Systems * ISTA Pharmaceuticals * King Pharmaceuticals * KV Pharmaceutical * Leiner Health Products * Martek Biosciences Corporation * S. E. Massengill Company * Miles Laboratories * Naurex * Nereus Pharmaceuticals * Nuvelo * Organon International * Ortho Pharmaceutical * OSI Pharmaceuticals * Parke-Davis * Qualitest * Schering-Plough * Smith, Kline ;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">v

* t * e

Components of the Dow Jones Industrial Average

* 3M * American Express * Apple * Boeing
Boeing
* Caterpillar * Chevron * Cisco Systems * Coca-Cola * Disney * DowDuPont * ExxonMobil * General Electric
General Electric
* Goldman Sachs
Goldman Sachs
* The Home Depot
The Home Depot
* Intel
Intel
* IBM
IBM
* Johnson & Johnson * JPMorgan Chase
JPMorgan Chase
* McDonald\'s * Merck & Co.
Merck & Co.
* Microsoft
Microsoft
* Nike * Pfizer
Pfizer
* Procter ;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none;">v

* t * e

New Brunswick, New Jersey
New Brunswick, New Jersey

HISTORY AND ARCHITECTURE

* Buccleuch Mansion * Delaware and Raritan Canal * Henry Guest House * National Register of Historic Places * Queens Campus * Tallest buildings * Voorhees Mall
Voorhees Mall
* Willow Grove Cemetery

ARTS AND ENTERTAINMENT

* Crossroads Theatre * George Street Playhouse
George Street Playhouse
* Grease trucks
Grease trucks
* Hungarian Festival * Mason Gross School of the Arts * Music scene * New Jersey Film Festival * New Jersey Folk Festival * State Theatre * The Stress Factory * Zimmerli Museum of Fine Art
Zimmerli Museum of Fine Art
* World Straight Pool Championship

GOVERNMENT AND EDUCATION

* Civic Square * Middlesex County College * New Brunswick Free Public Library
New Brunswick Free Public Library
* New Brunswick Main Post Office * New Brunswick Public Schools * Rutgers University * University of Medicine and Dentistry of New Jersey * Robert Wood Johnson Medical School
Robert Wood Johnson Medical School

ECONOMY AND HEALTHCARE

* Bristol-Myers Squibb * Cancer Institute of New Jersey * Hoagland Longo * Johnson border-left-width:2px;border-left-style:solid;width:100%;padding:0px">

* Boyd Park * Buccleuch Park * Delaware and Raritan Canal * East Jersey Olde Towne Village * Feaster Park * Johnson Park * Lawrence Brook
Lawrence Brook
* Lincoln Park * Mile Run * Raritan Landing * Rutgers Gardens
Rutgers Gardens
* Westons Mill Pond
Westons Mill Pond

TRANSPORTATION

* Jersey Avenue Station * New Brunswick Station * New Jersey Transit buses * Rutgers Campus Buses * Suburban Trails
Suburban Trails
* Route 18 * Route 27 * Route 91 * Route 172

NEIGHBORHOODS

* Civic Square * Edgebrook * Feaster Park * Fifth Ward * Lincoln Park * Livingston Avenue Historic District * Queens Campus * Raritan Gardens * Westons Mills

Coordinates : 40°29′55″N 74°26′37″W / 40.49861°N 74.44361°W / 40.49861; -74.44361

AUTHORITY CONTROL

* WorldCat Identities * VIAF : 157894482 * LCCN : no94000514 * ISNI : 0000 0001 2113 0582 * GND : 272550-2 * SUDOC : 175113343

Retrieved from "https://en.wikipedia.org/w/index.php?title=Johnson_%26_Johnson&oldid=809226321" Categories :

* Companies listed on the New York Stock Exchange * 1886 establishments in New Jersey * Companies based in New Brunswick, New Jersey
New Brunswick, New Jersey
* American companies established in 1886 * Dental companies * Companies in the Dow Jones Industrial Average * Johnson additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy .® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.

* Privacy policy * About * Disclaimers * Contact * Developers * Cookie statement * Mobile view

* *

Links: ------

.